We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
BioNTech SE Sponsored ADR (BNTX - Free Report) closed at $159.74 in the latest trading session, marking a +0.11% move from the prior day. This change lagged the S&P 500's 1.61% gain on the day. Elsewhere, the Dow gained 1.45%, while the tech-heavy Nasdaq added 0.36%.
Prior to today's trading, shares of the company had lost 6.2% over the past month. This has lagged the Medical sector's loss of 0.95% and the S&P 500's loss of 1.42% in that time.
Wall Street will be looking for positivity from BioNTech SE Sponsored ADR as it approaches its next earnings report date. This is expected to be May 9, 2022. The company is expected to report EPS of $9.07, up 71.46% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.53 billion, up 83.51% from the year-ago period.
BNTX's full-year Zacks Consensus Estimates are calling for earnings of $35.08 per share and revenue of $16.66 billion. These results would represent year-over-year changes of -25.19% and -25.52%, respectively.
It is also important to note the recent changes to analyst estimates for BioNTech SE Sponsored ADR. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.21% lower. BioNTech SE Sponsored ADR is currently a Zacks Rank #3 (Hold).
In terms of valuation, BioNTech SE Sponsored ADR is currently trading at a Forward P/E ratio of 4.55. This valuation marks a discount compared to its industry's average Forward P/E of 22.67.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 154, putting it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BNTX in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
BioNTech SE Sponsored ADR (BNTX - Free Report) closed at $159.74 in the latest trading session, marking a +0.11% move from the prior day. This change lagged the S&P 500's 1.61% gain on the day. Elsewhere, the Dow gained 1.45%, while the tech-heavy Nasdaq added 0.36%.
Prior to today's trading, shares of the company had lost 6.2% over the past month. This has lagged the Medical sector's loss of 0.95% and the S&P 500's loss of 1.42% in that time.
Wall Street will be looking for positivity from BioNTech SE Sponsored ADR as it approaches its next earnings report date. This is expected to be May 9, 2022. The company is expected to report EPS of $9.07, up 71.46% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.53 billion, up 83.51% from the year-ago period.
BNTX's full-year Zacks Consensus Estimates are calling for earnings of $35.08 per share and revenue of $16.66 billion. These results would represent year-over-year changes of -25.19% and -25.52%, respectively.
It is also important to note the recent changes to analyst estimates for BioNTech SE Sponsored ADR. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.21% lower. BioNTech SE Sponsored ADR is currently a Zacks Rank #3 (Hold).
In terms of valuation, BioNTech SE Sponsored ADR is currently trading at a Forward P/E ratio of 4.55. This valuation marks a discount compared to its industry's average Forward P/E of 22.67.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 154, putting it in the bottom 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BNTX in the coming trading sessions, be sure to utilize Zacks.com.